Vinorelbine-related tetraplegia due to severe peripheral neuropathy.
Vinorelbine
breast cancer
tetraplegia
Journal
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
ISSN: 1477-092X
Titre abrégé: J Oncol Pharm Pract
Pays: England
ID NLM: 9511372
Informations de publication
Date de publication:
27 Jul 2023
27 Jul 2023
Historique:
medline:
27
7
2023
pubmed:
27
7
2023
entrez:
27
7
2023
Statut:
aheadofprint
Résumé
Vinorelbine, a semi-synthetic vinca alkaloid with anticancer activity by binding to tubulin, has shown to be successful in the treatment of cancer types including advanced non-small cell lung cancer, uterine cancer, and metastatic breast cancer. Myelosuppression, hematological effects, nausea, vomiting, exhaustion, and neuropathy are some of the most typical side effects of vinorelbine. We discuss the unusual presentation of vinorelbine-induced tetraplegia in a breast cancer patient. A 66-year-old patient with breast cancer, who was followed up with adjuvant aromatase inhibitor therapy after mastectomy, presented with lung and bone metastases. She progressed in the follow-ups after receiving platinum and taxane chemotherapy, vinorelbine treatment was then started. The patient complained of weakness, weariness, and trouble walking after receiving a total dose of 180 mg. Tetraplegia was found after a neurological assessment. It was thought that vinorelbine was responsible for the recent acute weakness. The patient's vinorelbine treatment was stopped. During follow-up, upper extremity paresis regressed, while lower extremities muscle strength remained unchanged. Vinorelbine, frequently used in oncology practice, causes some side effects. Although very rare in the literature, in this case severe peripheral neuropathy has been reported in the follow-up of post-vinorelbine quadriparesis.
Identifiants
pubmed: 37499222
doi: 10.1177/10781552231191469
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM